Levels of lipoprotein(a) [Lp(a)] need to be reduced by substantially more than has been achieved in recent trials
Levels of lipoprotein(a) [LP(a)] need to be reduced substantially in order to have the same impact on coronary heart disease (CHD) risk as that seen with relatively modest reductions of low-density lipoprotein (LDL) cholesterol, suggests a large-scale analysis of trial data.
Source: Medscape
Related stories
- Saving the PASS system for the sake of England’s FH Services, for current and future generations
- The national Child Parent Screening Service (CPSS) pilot has been extended until October 2024
- Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
- how the NHS is working to deliver improved lipid management
- HEART UK 36th Annual Medical and Scientific Conference 2023 LIPIDS – THE BEST YET - CONFERENCE REVIEW
- Our new Lipidology Podcast
- Recently formed Lipoprotein(a) Taskforce publishes Call to Action to increase recognition and acceptance of Lp(a) as an ASCVD risk factor
- Lipoprotein (a) disorder gets SNOMED codes
- Would you like to update your knowledge of lipid management and have the opportunity to liaise with others working in this area?
- Familial Hypercholesterolaemia Gene Testing One-Day Online Workshop - Dates for 2023